Dizal a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation

MetaVia Inc. a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven

Porosome Therapeutics, Inc. today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer’s Disease (AD) research and treatment by offering

Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic

Dyne Therapeutics, Inc. a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug Administration

Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine

Madrigal Pharmaceuticals, Inc. today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like

He strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial announcement in April 2025, the collaboration has made remarkable progress

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250